Empowered Patient Podcast

David Hochman, CEO and Founder, Orchestra BioMed is bringing a partnership model to promote healthcare innovation particularly in the field of drug eluting balloons. Their lead product Virtue Sirolimus Angiofusion Balloon (SAB) is delivering an established therapeutic agent in interventional cardiology during balloon angioplasty without needing a stent permanent implant. This unique drug delivery solution encapsulates the drug in a balloon that has no coating and delivers the drug through micropores in the balloon to deliver the intended dose.

#CoronaryDisease #Angioplasty #InstentRestenosis #MedTech

OrchestraBioMed.com

Listen to the podcast here

David Hochman, CEO and Founder, Orchestra BioMed is bringing a partnership model to promote healthcare innovation particularly in the field of drug eluting balloons. Their lead product Virtue Sirolimus Angiofusion Balloon (SAB) is delivering an established therapeutic agent in interventional cardiology during balloon angioplasty without needing a stent permanent implant. This unique drug delivery solution encapsulates the drug in a balloon that has no coating and delivers the drug through micropores in the balloon to deliver the intended dose.

#CoronaryDisease #Angioplasty #InstentRestenosis #MedTech

OrchestraBioMed.com

Download the transcript here

Paula Ragan, CEO and President, X4 Pharmamceuticals is developing innovative approaches to treat patients suffering from rare diseases with an initial focus on WHIM syndrome, a rare disease of the immune system that has a basis in a genetic mutation. X4 is also focused on a rare form of lymphoma called Waldenstrom macroglobulinemia, a blood cancer also caused or driven by a gene mutation. The X4 drug mavorixafor is in capsule form and is a lifelong therapy that revs up the immune system by attaching to white blood cells.

#WHIMSyndrome #WHIM #RareGeneticDiseases #mavorixafor #CXCRA #Waldenstrom

X4Pharma.com

Listen to the podcast here

Paula Ragan, CEO and President, X4 Pharmaceuticals is developing innovative approaches to treat patients suffering from rare diseases with an initial focus on WHIM syndrome, a rare disease of the immune system that has a basis in a genetic mutation. X4 is also focused on a rare form of lymphoma called Waldenstrom macroglobulinemia, a blood cancer also caused or driven by a gene mutation. The X4 drug mavorixafor is in capsule form and is a lifelong therapy that revs up the immune system by attaching to white blood cells.

#WHIMSyndrome #WHIM #RareGeneticDiseases #mavorixafor #CXCRA #Waldenstrom

X4Pharma.com

Download the transcript here

Amit Kumar is President and CEO, Anixa Biosciences, a Silicon Valley based biopharmaceutical company focused on the prevention and treatment of cancer and now developing novel treatments for COVID-19. Using high performance computing, molecular modeling and virtual testing techniques, Anixa is focusing exclusively on the genetics and machinery of the virus and developing a new drug from scratch that targets the operation of the virus itself and can be formulated as a pill. Amit discusses the latest developments in Anixa's COVID-19 drug discovery program and the race underway to develop new therapeutics and vaccines.

@AnixaBio #COVID19 #coronavirus #COVID19Therapeutics

Anixa.com

Listen to the podcast here

Amit Kumar is President and CEO, Anixa Biosciences, a Silicon Valley based biopharmaceutical company focused on the prevention and treatment of cancer and now developing novel treatments for COVID-19. Using high performance computing, molecular modeling and virtual testing techniques, Anixa is focusing exclusively on the genetics and machinery of the virus and developing a new drug from scratch that targets the operation of the virus itself and can be formulated as a pill. Amit discusses the latest developments in Anixa's COVID-19 drug discovery program and the race underway to develop new therapeutics and vaccines.

@AnixaBio #COVID19 #coronavirus #COVID19Therapeutics

Anixa.com

Download the transcript here

Dr. Juan Dominguez-Bendala is Director of Stem Cell Development of Translational Research and Research Associate Professor of Surgery at the UHealth Diabetes Research Institute, Miami Miller School of Medicine. Juan talks about their recent research on the regeneration of the human pancreas using an innovative approach to keeping human pancreatic slices alive for a long time compared to current techniques where cells die quickly. This additional time allows researchers to explore beta cell regeneration in human cells to better understand how to treat type 1 diabetes.

@DiabetesResearch #diabetes #type1diabetes #pancreas

DiabetesResearch.org

Listen to the podcast here

Dr. Juan Dominguez-Bendala is Director of Stem Cell Development of Translational Research and Research Associate Professor of Surgery at the UHealth Diabetes Research Institute, Miami Miller School of Medicine. Juan talks about their recent research on the regeneration of the human pancreas using an innovative approach to keeping human pancreatic slices alive for a long time compared to current techniques where cells die quickly. This additional time allows researchers to explore beta cell regeneration in human cells to better understand how to treat type 1 diabetes.

@DiabetesResearch #diabetes #type1diabetes #pancreas

DiabetesResearch.org

Download the transcript here

Dr. Cameron Durrant, Chairman and CEO, Humanigen explains the condition called cytokine storm and how their research into GMCSF, the master switch of the cytokine storm, has led to the development of the drug lenzilumab, LENZ, that neutralizes GMCSF. Adding LENZ to Remdesivir has shown promising results in early clinical trials and Humanigen recently announced they have signed an agreement with the National Institutes of Health to test LENZ in a larger trial in the search for a therapeutic for COVID-19.

@humanigen #cytokinestorm #COVID19 #LENZ #Remdesivir #NIH

Humanigen.com

Listen to the podcast here.

Dr. Cameron Durrant, Chairman and CEO, Humanigen explains the condition called cytokine storm and how their research into GMCSF, the master switch of the cytokine storm, has led to the development of the drug lenzilumab, LENZ, that neutralizes GMCSF. Adding LENZ to Remdesivir has shown promising results in early clinical trials and Humanigen recently announced they have signed an agreement with the National Institutes of Health to test LENZ in a larger trial in the search for a therapeutic for COVID-19.

@humanigen #cytokinestorm #COVID19 #LENZ #Remdesivir #NIH

Humanigen.com

Download the transcript here